Long-Term Survival, Morbidity, Social Functioning and Risk of Disability in Patients with a Herpes Simplex Virus Type 1 or Type 2 Central Nervous System Infection, Denmark, 2000-2016

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Long-Term Survival, Morbidity, Social Functioning and Risk of Disability in Patients with a Herpes Simplex Virus Type 1 or Type 2 Central Nervous System Infection, Denmark, 2000-2016. / Hansen, Ann-Brit E; Vestergaard, Hanne T; Dessau, Ram B; Bodilsen, Jacob; Andersen, Nanna S; Omland, Lars H; Christiansen, Claus B; Ellermann-Eriksen, Svend; Nielsen, Lene; Benfield, Thomas; Sørensen, Henrik T; Andersen, Christian Ø; Lebech, Anne-Mette; Obel, Niels.

In: Clinical Epidemiology, Vol. 12, 2020, p. 745-755.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Hansen, A-BE, Vestergaard, HT, Dessau, RB, Bodilsen, J, Andersen, NS, Omland, LH, Christiansen, CB, Ellermann-Eriksen, S, Nielsen, L, Benfield, T, Sørensen, HT, Andersen, CØ, Lebech, A-M & Obel, N 2020, 'Long-Term Survival, Morbidity, Social Functioning and Risk of Disability in Patients with a Herpes Simplex Virus Type 1 or Type 2 Central Nervous System Infection, Denmark, 2000-2016', Clinical Epidemiology, vol. 12, pp. 745-755. https://doi.org/10.2147/CLEP.S256838

APA

Hansen, A-B. E., Vestergaard, H. T., Dessau, R. B., Bodilsen, J., Andersen, N. S., Omland, L. H., Christiansen, C. B., Ellermann-Eriksen, S., Nielsen, L., Benfield, T., Sørensen, H. T., Andersen, C. Ø., Lebech, A-M., & Obel, N. (2020). Long-Term Survival, Morbidity, Social Functioning and Risk of Disability in Patients with a Herpes Simplex Virus Type 1 or Type 2 Central Nervous System Infection, Denmark, 2000-2016. Clinical Epidemiology, 12, 745-755. https://doi.org/10.2147/CLEP.S256838

Vancouver

Hansen A-BE, Vestergaard HT, Dessau RB, Bodilsen J, Andersen NS, Omland LH et al. Long-Term Survival, Morbidity, Social Functioning and Risk of Disability in Patients with a Herpes Simplex Virus Type 1 or Type 2 Central Nervous System Infection, Denmark, 2000-2016. Clinical Epidemiology. 2020;12:745-755. https://doi.org/10.2147/CLEP.S256838

Author

Hansen, Ann-Brit E ; Vestergaard, Hanne T ; Dessau, Ram B ; Bodilsen, Jacob ; Andersen, Nanna S ; Omland, Lars H ; Christiansen, Claus B ; Ellermann-Eriksen, Svend ; Nielsen, Lene ; Benfield, Thomas ; Sørensen, Henrik T ; Andersen, Christian Ø ; Lebech, Anne-Mette ; Obel, Niels. / Long-Term Survival, Morbidity, Social Functioning and Risk of Disability in Patients with a Herpes Simplex Virus Type 1 or Type 2 Central Nervous System Infection, Denmark, 2000-2016. In: Clinical Epidemiology. 2020 ; Vol. 12. pp. 745-755.

Bibtex

@article{51c545dfc56d47a38be81e54b315963b,
title = "Long-Term Survival, Morbidity, Social Functioning and Risk of Disability in Patients with a Herpes Simplex Virus Type 1 or Type 2 Central Nervous System Infection, Denmark, 2000-2016",
abstract = "Background: The long-term prognosis following herpes simplex virus (HSV) central nervous system (CNS) infection is still debated.Patients and Methods: We examined outcomes in all Danish residents who, during 2000-2016, tested PCR positive for HSV-1 (n=208) or HSV-2 (n=283) in the cerebrospinal fluid, compared to comparison cohorts from the general population (n=2080 and n=2830).Results: One-year mortality was increased among HSV-1 patients (difference 19.3%; 95% CI: 13.6% to 25.0%) and HSV-2 patients (difference 5.3%; 95% CI: 2.5% to 8.1%), but thereafter mortality was not increased. After exclusion of persons diagnosed with cancer prior to study inclusion, one-year mortality difference for HSV-2 patients was 1.7% (-0.1% to 3.5%). After five years, HSV-1 patients had lower employment (difference -19.8%; 95% CI: -34.7% to -4.8%) and higher disability pension rates (difference 22.2%; 95% CI: 8.4% to 36.0%) than the comparison cohort, but similar number of inpatient days, outpatient visits, and sick leave. HSV-2 patients had employment and disability pension rates comparable to the comparison cohort, but more inpatient days (difference 1.5/year; 95% CI: -0.2 to 3.2), outpatient visits (difference 1.3/year; 95% CI: 0.3 to 3.2), and sick leave days (difference 9.1/year; 95% CI: 7.9 to 10.4).Conclusion: HSV-1 and HSV-2 CNS infections differ substantially with respect to prognosis. HSV-1 CNS infection is followed by increased short-term mortality and long-term risk of disability. HSV-2 CNS infection has no substantial impact on mortality or working capability but is associated with increased morbidity.",
author = "Hansen, {Ann-Brit E} and Vestergaard, {Hanne T} and Dessau, {Ram B} and Jacob Bodilsen and Andersen, {Nanna S} and Omland, {Lars H} and Christiansen, {Claus B} and Svend Ellermann-Eriksen and Lene Nielsen and Thomas Benfield and S{\o}rensen, {Henrik T} and Andersen, {Christian {\O}} and Anne-Mette Lebech and Niels Obel",
note = "{\textcopyright} 2020 Hansen et al.",
year = "2020",
doi = "10.2147/CLEP.S256838",
language = "English",
volume = "12",
pages = "745--755",
journal = "Clinical Epidemiology",
issn = "1179-1349",
publisher = "Dove Medical Press Ltd",

}

RIS

TY - JOUR

T1 - Long-Term Survival, Morbidity, Social Functioning and Risk of Disability in Patients with a Herpes Simplex Virus Type 1 or Type 2 Central Nervous System Infection, Denmark, 2000-2016

AU - Hansen, Ann-Brit E

AU - Vestergaard, Hanne T

AU - Dessau, Ram B

AU - Bodilsen, Jacob

AU - Andersen, Nanna S

AU - Omland, Lars H

AU - Christiansen, Claus B

AU - Ellermann-Eriksen, Svend

AU - Nielsen, Lene

AU - Benfield, Thomas

AU - Sørensen, Henrik T

AU - Andersen, Christian Ø

AU - Lebech, Anne-Mette

AU - Obel, Niels

N1 - © 2020 Hansen et al.

PY - 2020

Y1 - 2020

N2 - Background: The long-term prognosis following herpes simplex virus (HSV) central nervous system (CNS) infection is still debated.Patients and Methods: We examined outcomes in all Danish residents who, during 2000-2016, tested PCR positive for HSV-1 (n=208) or HSV-2 (n=283) in the cerebrospinal fluid, compared to comparison cohorts from the general population (n=2080 and n=2830).Results: One-year mortality was increased among HSV-1 patients (difference 19.3%; 95% CI: 13.6% to 25.0%) and HSV-2 patients (difference 5.3%; 95% CI: 2.5% to 8.1%), but thereafter mortality was not increased. After exclusion of persons diagnosed with cancer prior to study inclusion, one-year mortality difference for HSV-2 patients was 1.7% (-0.1% to 3.5%). After five years, HSV-1 patients had lower employment (difference -19.8%; 95% CI: -34.7% to -4.8%) and higher disability pension rates (difference 22.2%; 95% CI: 8.4% to 36.0%) than the comparison cohort, but similar number of inpatient days, outpatient visits, and sick leave. HSV-2 patients had employment and disability pension rates comparable to the comparison cohort, but more inpatient days (difference 1.5/year; 95% CI: -0.2 to 3.2), outpatient visits (difference 1.3/year; 95% CI: 0.3 to 3.2), and sick leave days (difference 9.1/year; 95% CI: 7.9 to 10.4).Conclusion: HSV-1 and HSV-2 CNS infections differ substantially with respect to prognosis. HSV-1 CNS infection is followed by increased short-term mortality and long-term risk of disability. HSV-2 CNS infection has no substantial impact on mortality or working capability but is associated with increased morbidity.

AB - Background: The long-term prognosis following herpes simplex virus (HSV) central nervous system (CNS) infection is still debated.Patients and Methods: We examined outcomes in all Danish residents who, during 2000-2016, tested PCR positive for HSV-1 (n=208) or HSV-2 (n=283) in the cerebrospinal fluid, compared to comparison cohorts from the general population (n=2080 and n=2830).Results: One-year mortality was increased among HSV-1 patients (difference 19.3%; 95% CI: 13.6% to 25.0%) and HSV-2 patients (difference 5.3%; 95% CI: 2.5% to 8.1%), but thereafter mortality was not increased. After exclusion of persons diagnosed with cancer prior to study inclusion, one-year mortality difference for HSV-2 patients was 1.7% (-0.1% to 3.5%). After five years, HSV-1 patients had lower employment (difference -19.8%; 95% CI: -34.7% to -4.8%) and higher disability pension rates (difference 22.2%; 95% CI: 8.4% to 36.0%) than the comparison cohort, but similar number of inpatient days, outpatient visits, and sick leave. HSV-2 patients had employment and disability pension rates comparable to the comparison cohort, but more inpatient days (difference 1.5/year; 95% CI: -0.2 to 3.2), outpatient visits (difference 1.3/year; 95% CI: 0.3 to 3.2), and sick leave days (difference 9.1/year; 95% CI: 7.9 to 10.4).Conclusion: HSV-1 and HSV-2 CNS infections differ substantially with respect to prognosis. HSV-1 CNS infection is followed by increased short-term mortality and long-term risk of disability. HSV-2 CNS infection has no substantial impact on mortality or working capability but is associated with increased morbidity.

U2 - 10.2147/CLEP.S256838

DO - 10.2147/CLEP.S256838

M3 - Journal article

C2 - 32765109

VL - 12

SP - 745

EP - 755

JO - Clinical Epidemiology

JF - Clinical Epidemiology

SN - 1179-1349

ER -

ID: 251996004